Suven Pharmaceuticals Ltd Analyst Rating
based on 2 analysts
50.00%
Buy
0.00%
Hold
50.00%
Sell
Based on 2 analysts offering long term price targets for Suven Pharmaceuticals Ltd. An average target of ₹950.5
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Share analysis
Suven Pharmaceuticals Ltd price forecast by 2 analysts
Downside of
High
₹1330
Target
₹950.50
Low
₹571
Suven Pharmaceuticals Ltd target price ₹950.5, a slight downside of -26.61% compared to current price of ₹1295.15. According to 2 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Suven Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:117.10%
Forecast
Actual
Including amortisation and stock based compensations
Suven Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:63.56%
Forecast
Actual
Source: S&P Global Market Intelligence
Suven Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,274.45₹1,303.1552 Week's Low
52 Week's High
₹577₹1,353.95
| Returns % | |
| 1 Month Return | + 3.6 % |
| 3 Month Return | + 20.91 % |
| 1 Year Return | + 110.92 % |
| Market Stats | |
| Previous Close | ₹1,274.45 |
| Open | ₹1,279.00 |
| Volume | 6.08L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹32,443.03Cr |
Suven Pharmaceuticals Ltd Key Statistics
| P/E Ratio | 135.48 |
| PEG Ratio | -18.28 |
| Market Cap | ₹32,443.03 Cr |
| P/B Ratio | 8.38 |
| EPS | 11.8 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 14.31 |
Suven Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹32,443.03 Cr | 133.7% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹18,006.48 Cr | 29.79% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹6,176.62 Cr | 3.81% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹15,982.20 Cr | 50.41% | 0.68 | ₹218 Cr | ₹1,296 Cr | |
| BUY | ₹26,233.73 Cr | 225.63% | 0.55 | ₹258 Cr | ₹1,375 Cr |
About Suven Pharmaceuticals Ltd
Share Price: ₹1295.15 per share as on 22 Nov, 2024 04:01 PM
Market Capitalisation: ₹32,443.03Cr as of today
Revenue: ₹257.72Cr as on September 2024 (Q3 24)
Net Profit: ₹81.98Cr as on September 2024 (Q3 24)
Listing date: 05 Mar, 2020
Chairperson Name: Annaswamy Vaidheesh
| Organisation | Suven Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Suven Pharmaceuticals Ltd
Suven Pharma Reports Growth in Q3 2024 Financials - 14 Nov, 2024
Suven Pharmaceuticals reported a 5.09% increase in standalone net sales to Rs 236.06 crore for September 2024. Net profit rose by 2.15% to Rs 76.33 crore, while EBITDA increased by 2.59%. EPS improved to Rs 3.00 from Rs 2.94 in the previous year.
Suven Pharma Reports Positive Q2 Earnings Growth - 13 Nov, 2024
Suven Pharmaceuticals' Q2FY25 results show a 3.34% increase in net profit to Rs 82 crore, with revenue growth driven by the CDMO sector and the acquisition of Sapala Organics. Despite a drop in profit before tax, the company maintains a positive outlook for future growth.
NCLT Approves Merger of Casper Pharma and Suven Pharmaceuticals - 29 Oct, 2024
The National Company Law Tribunal has approved the merger of Casper Pharma with Suven Pharmaceuticals, enhancing operational efficiency and creating new revenue opportunities. Suven aims to optimize costs and retain key talent through employee stock options.
Insights on Suven Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 9.80% to 10.70% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 46.75 Cr → 82.21 Cr (in ₹), with an average increase of 16.9% per quarter
- POSITIVE IMPACT
Price Rise
In the last 6 months, SUVENPHAR stock has moved up by 105.5%
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 248.85 Cr → 271.84 Cr (in ₹), with an average increase of 8.5% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, SUVENPHAR has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 50.10% of holdings in Sep 2024 quarter
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 22.67% to 22.25% in Sep 2024 quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 14.78% to 14.12% in Sep 2024 quarter
Suven Pharmaceuticals Ltd Financials
Index Inclusions
Suven Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 50.1% | 0.00 | |
| Foreign Institutions | 10.7% | 9.15 | |
| Mutual Funds | 14.12% | ||
| Retail Investors | 22.25% | ||
| Others | 2.84% | 6.91 |
Suven Pharmaceuticals Ltd Key Indicators
Suven Pharmaceuticals Ltd Valuation
Suven Pharmaceuticals Ltd in the last 5 years
Lowest (4.48x)
March 30, 2020
Industry (54.77x)
November 22, 2024
Today (135.48x)
November 22, 2024
Highest (139.56x)
November 5, 2024
Suven Pharmaceuticals Ltd Earnings and Dividends
Suven Pharmaceuticals Ltd Earnings Results
Suven Pharmaceuticals Ltd’s net profit jumped 3.33% since last year same period to ₹82.21Cr in the Q2 2024-2025. On a quarterly growth basis, Suven Pharmaceuticals Ltd has generated 35.28% jump in its net profits since last 3-months.
Read More about Earnings ResultsSuven Pharmaceuticals Ltd Dividends September,2022
In the quarter ending June 2022, Suven Pharmaceuticals Ltd has declared dividend of ₹1 - translating a dividend yield of 0.85%.
Read More about Dividends
Suven Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Suven Pharmaceuticals Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Suven Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Suven Pharmaceuticals Ltd shares.
Suven Pharmaceuticals Ltd (SUVENPHAR) share price today is ₹1295.15
Suven Pharmaceuticals Ltd is listed on NSE
Suven Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Suven Pharmaceuticals Ltd is ₹1303.15.
- Today’s lowest price of Suven Pharmaceuticals Ltd is ₹1274.45.
PE Ratio of Suven Pharmaceuticals Ltd is 135.48
PE ratio = Suven Pharmaceuticals Ltd Market price per share / Suven Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Suven Pharmaceuticals Ltd(SUVENPHAR) is 6.08L.
Today’s market capitalisation of Suven Pharmaceuticals Ltd(SUVENPHAR) is ₹32443.03Cr.
| Suven Pharmaceuticals Ltd(SUVENPHAR | Price |
|---|---|
52 Week High | ₹1353.95 |
52 Week Low | ₹577 |
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1295.15. It is down -4.34% from its 52 Week High price of ₹1353.95
Suven Pharmaceuticals Ltd(SUVENPHAR) share price is ₹1295.15. It is up 124.46% from its 52 Week Low price of ₹577
| Suven Pharmaceuticals Ltd(SUVENPHAR | Returns |
|---|---|
1 Day Returns | 20.7% |
1 Month Returns | 3.6% |
3 Month Returns | 20.91% |
1 Year Returns | 110.92% |